CA-MATRIXX-SOFTWARE
11.6.2019 10:02:11 CEST | Business Wire | Press release
MATRIXX Software , an innovation powerhouse committed to transforming global commerce, today announced that Roshan, Afghanistan’s leading telecommunications service provider, has selected MATRIXX Digital Commerce to transform their operations and grow revenue.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190611005211/en/
Roshan is partnering with MATRIXX Software to change the way its six million customers use telecom services by bringing real-time digital experience and personalization for all voice, data and digital services.
MATRIXX has a global customer footprint across Europe, the Middle East, Asia and North America. Roshan selected MATRIXX because it is the only vendor providing a single platform that both protects and grows revenues from traditional prepaid voice and messaging services while also delivering the tools to attract smartphone users and increase data usage. As the digital revolution sweeps through emerging markets, mobile operators need cost effective, scalable solutions that improve their existing operating portfolios while building for the future of smartphones and digital service revenues.
In a signing ceremony in Dubai, UAE, Roshan’s CEO Karim Khoja said, “Since our founding, Roshan has always embraced implementing new technologies and applications to provide our customers with the best experience. This partnership with MATRIXX Software showcases that the digital experience is quickly becoming a reality in Afghanistan.”
“Afghanistan’s communications infrastructure has come a long way in 16 years and Roshan has played and continues to play a significant role in making that happen,” said Dave Labuda, MATRIXX Software co-founder and CEO. “It is only natural that Roshan is leading the way into a new era of digital connectivity. We are proud to be a part of helping Roshan deliver the future of customer experience and service innovation that Roshan aims to bring to their customers.”
Built entirely from scratch, the multi-patented, award-winning MATRIXX Digital Commerce Platform enables a digital-first reinvention of Telco BSS. It brings together traditionally separate network and IT functions into a single platform including product design and lifecycle management, customer engagement, service delivery and monetization. Built for digital, the MATRIXX Digital Commerce Platform offers operators the agility and seamless scalability required to compete and win now and in the future.
Roshan has always been a pioneer in leveraging its robust network infrastructure and technology to support the government and the people of Afghanistan. These include the launch of Afghanistan’s first ever mobile money service, M-Paisa, which has contributed to increasing financial transparency and financial inclusion. Roshan also launched the first Telemedicine program in Afghanistan in 2007, linking hospitals in Badakhshan, Bamiyan and Kandahar provinces to the French Medical Institute for Children and Mothers (FMIC) in Kabul, one of the most modern hospitals in the country. Since its launch, almost 30,000 patients across Afghanistan have received treatment through this telemedicine link.
About Roshan
Roshan (Telecom Development Company Afghanistan Ltd) is Afghanistan's leading total communications provider with 6 million active subscribers and a network that covers over 287 districts and cities in all of the country's 34 provinces.
Roshan is a true Afghanistan success story, serving as a catalyst for economic growth and actively contributing to the country’s long-term development. Since its inception in 2003, Roshan has invested approximately $750 million in Afghanistan and is the country’s single largest private investor and taxpayer, contributing approximately five percent of the Afghan government's overall domestic revenue. Roshan directly employs around 900 people, 20 percent of whom are women, and provides indirect employment to more than 35,000 people. Roshan is deeply committed to Afghanistan’s reconstruction and development.
The Aga Khan Fund for Economic Development (AKFED), part of the Aga Khan Development Network (AKDN), is a major shareholder of Roshan and promotes private initiatives and building economically sound enterprises in the developing world. Also owned in part by Monaco Telecom International (MTI) and Telia, Roshan brings international expertise to the country and is committed to the highest standards of network quality and coverage for the people of Afghanistan.
To learn more about Roshan visit www.roshan.af or http://www.facebook.com/RoshanConnects . You can also follow us on Twitter @roshanconnects .
About MATRIXX Software
MATRIXX Software provides next-generation, cloud native digital commerce solutions that transform how companies do business. Serving many of the world’s largest communications companies, IoT players and emerging digital service providers, MATRIXX is committed to delivering a modern commerce platform that easily scales to support global market places and consumption-based services. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to reinvent themselves and succeed as a digital leader.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005211/en/
Contact:
Mercury Global Partners for MATRIXX Software Natalee Gibson, Managing Director matrixx@mercuryglobalpartners.com +1 720 648 5784
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom